TEKTURNA / NOVARTIS: Y ahora ? Lead the way...

"I had an excel spreadshseet that had everybody’s payments – all these physicians across the US. It was a lot of money and I knew the quality of what had gone on at these medical education events. There would be a doctor who could barely speak English, but wrote a lot of Tekturna (prescriptions). He had a pretty high market share relative to another physician in the same practice who didn’t speak for Tekturna. So he would be a speaker and get paid. It’s not very hard to put together the numbers, especially when you launch a drug and track it…But management would say you couldn’t use someone (as a speaker) if they didn’t write a lot of Tekturna, even if the person was an authority." (Más)

Jeremy Garrity worked (six years) for Novartis promoting various cardiovascular medicines, such as Diovan and Tekturna

Y ahora...

The study demonstrated that the trial arm in which Rasilez/Tekturna was added to the standard of care showed an increased incidence after 18-24 months of non-fatal stroke, renal complications, hyperkalemia and hypotension in the high-risk study population.

The committee reported that patients receiving Rasilez/Tekturna were unlikely to benefit from treatment added on top of standard anti-hypertensives, and also observed higher adverse events over standard of care. (Más)

Ver también/ Lead the way...:

Novartis hopes of blockbuster status for Rasilez dashed

NOVARTIS: La hace y...lo paga (caro).